Vascular dementia

Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years

Tuesday, September 14, 2021 - 2:10pm

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.

Key Points: 
  • Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.
  • A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia.
  • Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation.
  • This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable.

DiaMedica Therapeutics Initiates Pivotal Trial of DM199 for the Treatment of Acute Ischemic Stroke

Monday, September 13, 2021 - 1:32pm

The ReMEDy2 Trial is a randomized, double-blind, placebo-controlled Phase 2/3 adaptive trial designed to enroll 350 patients at 75 sites in the United States.

Key Points: 
  • The ReMEDy2 Trial is a randomized, double-blind, placebo-controlled Phase 2/3 adaptive trial designed to enroll 350 patients at 75 sites in the United States.
  • DM199 is currently being studied in patients with acute ischemic stroke and chronic kidney disease.
  • DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases.
  • DiaMedicas lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality for the treatment of acute ischemic stroke and chronic kidney disease.

The IMA Group Continues Growth with Acquisition of Albuquerque Neuroscience, Inc.

Thursday, September 9, 2021 - 12:02pm

The IMA Group (IMA) announced today the acquisition of Albuquerque Neuroscience, Inc., a clinical research site specializing in diseases of the central nervous system (CNS) and general medical conditions.

Key Points: 
  • The IMA Group (IMA) announced today the acquisition of Albuquerque Neuroscience, Inc., a clinical research site specializing in diseases of the central nervous system (CNS) and general medical conditions.
  • Albuquerque Neuroscience joins IMAs Clinical Research Division , which specializes in Phase II-IV clinical trials in all therapeutic areas.
  • The acquisition adds another high-quality clinical trial site to IMA Clinical Research while further expanding its national footprint.
  • IMA Clinical Research, a division of The IMA Group, is a physician-founded network of integrated clinical research sites specializing in Phase II-IV clinical trials in multiple therapeutic areas.

$44 Million NIH Grant to See if Dementia Can Be Prevented

Tuesday, April 6, 2021 - 1:00pm

This new grant furthers prior research, published as findings of the ACTIVE Study in 2017 , that showed a small amount of cognitive training significantly reduced the risk and incidence of dementia among older adults.

Key Points: 
  • This new grant furthers prior research, published as findings of the ACTIVE Study in 2017 , that showed a small amount of cognitive training significantly reduced the risk and incidence of dementia among older adults.
  • This study addresses the central question that most people have about brain training does training your brain reduce your chances of dementia?
  • Researchers reported an up to 48 percent reduction in dementia incidence among people who asked to complete up to 18 hours of training and an overall 29 percent reduction in dementia risk.
  • Its gratifying to see the NIH going the distance building on the established science of brain training to answer the crucial question of dementia prevention, Dr. Mahncke observed.

SciSparc to Conduct a Phase IIa Clinical Trial in Alzheimer's Patients Using the Company's Proprietary Cannabinoid-Based Treatment

Wednesday, February 17, 2021 - 1:30pm

Alzheimer's disease is the most common type of dementia, accounting for over two-thirds of cases of dementia.

Key Points: 
  • Alzheimer's disease is the most common type of dementia, accounting for over two-thirds of cases of dementia.
  • Alzheimer's disease is a neurodegenerative disease that causes progressive and disabling impairment of cognitive functions including memory, comprehension, language, attention, reasoning and judgment.
  • The current pharmacological treatment of agitation in Alzheimer's disease has an unsatisfactory benefit/risk ratio and often involves using off-label drugs.
  • The Alzheimer's center treats hundreds of patients a year, as inpatients, outpatients and as part of its diagnosis and counseling services.

Rackspace Technology migrates the British Heart Foundation’s online gift shop to VMware

Monday, December 14, 2020 - 8:00am

LONDON, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Rackspace Technology (NASDAQ: RXT), the multicloud solutions provider, has extended its work with the British Heart Foundation to provide support to its online gift shop ahead of Christmas.

Key Points: 
  • LONDON, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Rackspace Technology (NASDAQ: RXT), the multicloud solutions provider, has extended its work with the British Heart Foundation to provide support to its online gift shop ahead of Christmas.
  • The global pandemic has severely hampered fundraising and retail sales for many charities including the British Heart Foundation (BHF).
  • This piece of work has supported our online shop to continue raising vital funds for heart research.
  • Each year, British Heart Foundation (BHF) shops raisemillionsto help the BHF fund life-saving research into all heart diseases, stroke, vascular dementia and diabetes.

Eisai: Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer's Disease Using Blood

Monday, November 9, 2020 - 12:08am

Of these sufferers, those living with AD are thought to account for more than 60% of those living with dementia.

Key Points: 
  • Of these sufferers, those living with AD are thought to account for more than 60% of those living with dementia.
  • (10)
    Sysmex and Eisai are working to create new diagnostic technologies for the prevention and treatment of dementia.
  • (1) A standardization scale for integration analysis of PET SUVR values as measured by different amyloid PET imaging probes.
  • * This finding was expected to lead to the development of a simple method of diagnosing Alzheimer's disease using blood.

Global Dementia with Diabetes Market 2017-2030: Epidemiology, Pipeline, Drugs, Competitive Intelligence

Monday, August 24, 2020 - 6:00pm

The report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Dementia with Diabetes market size from 2017 to 2030.

Key Points: 
  • The report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Dementia with Diabetes market size from 2017 to 2030.
  • The report also covers current Dementia with Diabetes treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
  • In US (2017), the estimated cases of type specific dementia for Alzheimer's disease, vascular dementia, Lewy-body dementia, Fronto-temporal dementia, mixed dementia and others are 5,796,827, 1,337,729, 535,092, 89,182, 713,456 and 445,910.
  • The publisher performs competitive and market intelligence analysis of the Dementia with Diabetes market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc.

Dementia with Diabetes: Market Insights, Epidemiology & Forecast 2030 - ResearchAndMarkets.com

Thursday, August 20, 2020 - 4:01pm

The "Dementia with Diabetes - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dementia with Diabetes - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Dementia with Diabetes market size from 2017 to 2030.
  • The report also covers current Dementia with Diabetes treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
  • In US (2017), the estimated cases of type specific dementia for Alzheimer's disease, vascular dementia, Lewy-body dementia, Fronto-temporal dementia, mixed dementia and others are 5,796,827, 1,337,729, 535,092, 89,182, 713,456 and 445,910.

Heart Health Problems in Your 20s May Affect Brain Health Decades Later

Thursday, February 27, 2020 - 1:37pm

The study involved 189 people with an average age of 24 who were followed for 30 years as part of a larger study.

Key Points: 
  • The study involved 189 people with an average age of 24 who were followed for 30 years as part of a larger study.
  • Each time, their cardiovascular health was assessed based on five factors: smoking, BMI, blood pressure, total cholesterol and fasting blood glucose level.
  • "More focus on a life course research approach is needed to help us better understand how these vascular risk factors affect brain health as we age," Sorond said.
  • Learn more about brain health at BrainandLife.org , home of the American Academy of Neurology's free patient and caregiver magazine focused on the intersection of neurologic disease and brain health.